PriceTargets.com logo

Aligos Therapeutics - ALGS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 599.30%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.72 As of 12/5/2023 10:51 AM ET
▲ +0.035 (5.15%)

This chart shows the closing price for ALGS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aligos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALGS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALGS

Analyst Price Target is $5.00
▲ +599.30% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aligos Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $7.00 and a low forecast of $3.00. The average price target represents a 599.30% upside from the last price of $0.72.

This chart shows the closing price for ALGS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Aligos Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2023Piper SandlerBoost Target$3.00 ➝ $7.00Low
1/6/2023Piper SandlerUpgradeNeutral ➝ Overweight$2.00 ➝ $3.00Low
1/6/2023Jefferies Financial GroupUpgradeHold ➝ Buy$2.50 ➝ $3.00Low
11/3/2022SVB LeerinkLower TargetMarket Perform$3.00 ➝ $2.00Low
8/8/2022Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
6/8/2022Cantor FitzgeraldReiterated RatingOverweightHigh
5/5/2022SVB LeerinkDowngradeOutperform ➝ Market PerformHigh
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/23/2022SVB LeerinkLower TargetOutperform$11.00 ➝ $7.00High
3/23/2022Piper SandlerDowngradeOverweight ➝ Neutral$15.00 ➝ $4.00High
3/11/2022Piper SandlerLower TargetOverweight$47.00 ➝ $15.00High
3/11/2022SVB LeerinkBoost TargetOutperform$10.00 ➝ $11.00High
2/16/2022SVB LeerinkLower TargetOutperform$15.00 ➝ $10.00Medium
1/7/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$30.00 ➝ $12.00High
1/7/2022SVB LeerinkLower TargetOutperform$29.00 ➝ $15.00High
1/6/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$20.00 ➝ $5.00High
9/9/2021SVB LeerinkInitiated CoverageOutperform$29.00Medium
5/17/2021Piper SandlerInitiated CoverageOverweight$47.00 ➝ $35.00High
4/1/2021Jefferies Financial GroupReiterated RatingBuy$42.00High
3/24/2021Piper SandlerBoost TargetOverweight$35.00 ➝ $40.00High
11/10/2020Jefferies Financial GroupInitiated CoverageBuy$26.00High
11/10/2020JPMorgan Chase & Co.Initiated CoverageOverweight$33.00High
11/10/2020Piper SandlerInitiated CoverageOverweight$35.00High
11/10/2020Cantor FitzgeraldInitiated CoverageOverweight$28.00High
(Data available from 12/5/2018 forward)

News Sentiment Rating

1.06 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/8/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2023

Current Sentiment

  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Aligos Therapeutics logo
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $0.72
Low: $0.70
High: $0.74

50 Day Range

MA: $0.71
Low: $0.59
High: $0.80

52 Week Range

Now: $0.72
Low: $0.54
High: $2.41

Volume

2,593 shs

Average Volume

196,723 shs

Market Capitalization

$53.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Aligos Therapeutics?

The following Wall Street analysts have issued reports on Aligos Therapeutics in the last twelve months: Jefferies Financial Group Inc., and Piper Sandler.
View the latest analyst ratings for ALGS.

What is the current price target for Aligos Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Aligos Therapeutics in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 623.6%. Piper Sandler has the highest price target set, predicting ALGS will reach $7.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $3.00 for Aligos Therapeutics in the next year.
View the latest price targets for ALGS.

What is the current consensus analyst rating for Aligos Therapeutics?

Aligos Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALGS will outperform the market and that investors should add to their positions of Aligos Therapeutics.
View the latest ratings for ALGS.

What other companies compete with Aligos Therapeutics?

Other companies that are similar to Aligos Therapeutics include Estrella Immunopharma, Dyadic International, Athira Pharma, AVROBIO and Precision BioSciences. Learn More about companies similar to Aligos Therapeutics.

How do I contact Aligos Therapeutics' investor relations team?

The company's listed phone number is 800-466-6059 and its investor relations email address is [email protected]. The official website for Aligos Therapeutics is www.aligos.com. Learn More about contacing Aligos Therapeutics investor relations.